retatrutide and heart Does Cause Problems? What the Research Actually Shows Retatrutide—A Game Changer in Obesity

doi: 10.1161/CIRCULATIONAHA.125.074545 Summary Keywords cardiovascular outcomes, SGLT2 inhibitors, GLP-1 agonists, combination therapy, heart failure, renal outcomes Citation Aristizbal-Colorado D, Corredor-Rengifo D, Sierra-Castillo S, Lpez-Corredor C, Vernaza-Trujillo D-A, Weir-Restrepo D, Izquierdo-Condoy JS, Ortiz-Prado E, Rico-Fontalvo J, Gmez-Mesa J-E, Abreu-Lomba A and Rivera-Martnez W-A (2025) A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists a comprehensive review

FDA label (PDF) U.S

Using it would produce unreliable results and is not recommended

The Asia Pacific region is expected to experience the highest CAGR during the forecast period Asia Pacific is expected to grow with the fastest CAGR owing to rising type 2 diabetes cases and increasing healthcare accessibility